Luly

Quick links to important sections

Luly

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Luly

What is Luly? Definition and Purpose

Luly is a Topical Antifungal medicine formulated with the synthetic compound Luliconazole and used exclusively for the external treatment of fungal skin conditions. This active agent is classified as an Azole antifungal (an azole derivative), a class of medication clinically recognized for its ability to target and interfere with the fungal cell structure.


Property Description
Active Ingredient Luliconazole
Form Cream (1%), Lotion
Pharmacological Class Azole Antifungal / Imidazole Derivative
General Purpose Eradication of Fungal Skin Infections
Origin Synthetic Compound

The Classification and Differentiating Features of Luly

The classification of Luly is key to understanding its action: Luliconazole is recognized as a modern, high-efficacy imidazole derivative. The product is strictly for the topical application route and is provided in multiple distinct dosage form(s), notably a Cream and a Lotion. This differentiation in vehicle allows for flexibility when treating various locations and extents of infection, such as when the Lotion form is preferred for hairier areas. The formulation utilizes a vehicle base that often includes excipients such as Benzyl Alcohol along with the Luliconazole.

Therapeutic Action and General Purpose

The general therapeutic purpose of Luly is the swift and definitive eradication of fungal pathogens. It is a powerful fungicidal agent, meaning it actively kills the fungi rather than merely inhibiting growth. This potent mechanism is achieved by interfering with the fungal cell membrane's vital structure; Luliconazole works by inhibiting the synthesis of ergosterol, a necessary component for the membrane. This action is designed to cause the rapid breakdown of the fungal organism, which is essential for fully clearing the infection and alleviating the associated discomforts of common fungal skin conditions.

Regulatory References

  1. FDA Prescribing Information

What side effects are possible with Luly?

Possible side effects and safety information

The safety profile of Luly (Luliconazole) is documented primarily by localized reactions at the application site, as detailed in official government regulatory documents.


Adverse Reactions and Regulatory Classification

The adverse reactions observed in clinical trials are largely classified under Skin and Subcutaneous Tissue Disorders.

Classification Adverse Reaction Regulatory Status
Less than 1% Application site reactions Clinical Trials Data
Frequency Not Estimated Contact dermatitis, Cellulitis Post-Marketing Surveillance

Application site reactions were the most frequent adverse event reported in controlled clinical trials, occurring in less than 1% of subjects. The more clinically significant events, contact dermatitis and cellulitis, have been reported through voluntary post-marketing surveillance, meaning their frequency cannot be reliably estimated.


Safety Constraints and Special Populations

Luly is strictly for topical use only and is not intended for ophthalmic or intravaginal administration. The medication is contraindicated in individuals with a known hypersensitivity to Luliconazole or any component of the formulation.

  • Pediatric Safety: Safety and effectiveness have not been established for the treatment of Tinea Pedis or Tinea Cruris in children under 12 years of age, or for Tinea Corporis in children under 2 years of age.
  • Pregnancy and Lactation: There is no available data concerning the use in pregnant women. Low systemic absorption is noted, but no information exists on its presence in human milk or effects on a breastfed infant.
  • Systemic Safety Note: Luliconazole may inhibit CYP2C19 and CYP3A4 enzymes, a high-level safety consideration noted in regulatory documents, particularly when applied over large surface areas.

Overdose and Emergency Response

Overdose and When to Seek Help

The topical formulation of Luly (Luliconazole) is characterized by minimal systemic absorption through the skin. For this reason, official regulatory prescribing information states that systemic overdose symptoms are not documented following the application of excess amounts.

However, specific emergency actions are mandated by health authorities for accidental exposure scenarios:

Scenario Required Action
Accidental Oral Ingestion Seek immediate medical attention or call a Poison Control Center immediately. If the individual is collapsed or not breathing, local emergency services must be contacted without delay.
Ocular Exposure The affected eye must be immediately and thoroughly flushed with cool, clean water.

Management and Treatment

Official regulatory documentation confirms that no specific antidote is available for Luliconazole. Therefore, the mandated clinical management following any overdose event is strictly symptomatic and supportive treatment.

The primary regulatory mandate for seeking urgent medical help is related to accidental oral ingestion, particularly if severe outcomes such as collapse or cessation of breathing occur. The labels do not contain specific overdose management protocols or heightened risks for special populations, such as those with hepatic or renal impairment.

Therapeutic Uses of Luly

Luly is commonly used to provide effective therapeutic support for a specific group of fungal skin conditions known as dermatophytoses, and is commonly used to help with the targeted management of the pathogen. Luliconazole is generally used to help address common fungal infections of the skin like athlete's foot, jock itch, and ringworm.

The medication is relevant in clinical settings for conditions presenting with Tinea Pedis (Athlete's Foot between the toes), Tinea Cruris (Jock Itch), and Tinea Corporis (Ringworm of the body). It can help address symptom clusters that may become intense or disruptive, such as pruritus (itching), burning, and noticeable scaling or flaking of the skin. This provides supportive relief that helps ease the overall symptom burden. The use of Luly is relevant for managing infections in areas that are characterized by warmth and moisture.

“The medication may assist with managing the physical signs of epidermal damage, including cracking and fissuring.”


Quick Fact: Relief for Itching and Burning
Luly is considered relevant for managing symptoms related to inflammation and skin breakdown, which contributes to easing overall discomfort.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Luly?

Eligibility for Luly (Luliconazole Topical Cream) is strictly defined by regulatory labeling based on patient population, age, and physiological status.

Contraindications and Restrictions

The medicine is contraindicated for any individual with a known hypersensitivity or allergy to luliconazole or any component of the formulation. Beyond this, regulatory documents generally state there are no absolute comorbidity-based contraindications.

Population Group Eligibility Status Key Restriction/Note
Tinea Pedis/Cruris (Children) Use Not Established Not for children younger than 12 years of age for these conditions.
Tinea Corporis (Children) Use Not Established Not for children younger than 2 years of age for this condition.
Pregnancy Conditional Use Use only if the potential benefit justifies the potential risk to the fetus (Pregnancy Category C).
Lactation Caution Exercised Use requires caution, as it is unknown if luliconazole is excreted in human milk.
Renal/Hepatic Impairment Permitted No dosage adjustment is required for patients with impaired kidney or liver function.

Approved Populations

Luly is approved for use in adults (18 years and older) for all labeled indications. Safety and effectiveness were established for children 12 years and older (Tinea Pedis/Cruris) and children 2 years and older (Tinea Corporis). No overall differences in safety were noted in older adults (65+), though greater individual sensitivity cannot be ruled out.

What should I know about interactions with other medicines?

Luly, a topical antifungal containing luliconazole, is generally considered to have a low risk for systemic drug-drug interactions due to its limited absorption through the skin following external application.

Potential Drug-Drug Interactions

Clinical studies have not been conducted to formally evaluate the interaction potential of Luly with other medicines. However, based on laboratory assessments (in vitro data), luliconazole demonstrates the potential to inhibit certain Cytochrome P450 (CYP) enzymes, specifically CYP2C19 and CYP3A4. These enzymes are responsible for metabolizing many prescription and over-the-counter drugs in the body.

This inhibitory potential is primarily relevant when Luly is applied over large surface areas, such as in the treatment of moderate-to-severe tinea cruris, where systemic absorption may be increased. If Luly were to inhibit these enzymes, it could theoretically lead to increased concentrations of other medications that are substrates of CYP2C19 or CYP3A4, potentially raising the risk of adverse effects from those co-administered drugs.

Interaction Risk Classification
Increased concentration of CYP2C19/CYP3A4 substrates Theoretical/Low Systemic Risk

Other Interactions

There are no known restrictions related to food, alcohol, or other topical products explicitly documented in most official labeling for Luly, but consulting a healthcare professional about the use of other topical medicines in the same area is recommended.

Mechanism of Action

Molecular Mechanism and Cellular Failure

The function of Luliconazole is achieved through a fungicidal process focused on structural failure within fungal cellular pathways. The mechanism initiates at the molecular level with the enzyme Lanosterol 14alpha-Demethylase ( CYP51). Luliconazole acts as an inhibitor of this enzyme, which catalyzes a step in the Ergosterol Biosynthesis Pathway. This inhibitory action creates a metabolic block, halting the production of ergosterol—a primary structural sterol of the fungal cell membrane.

The inhibition triggers a dual mechanistic cascade: a depletion of ergosterol and the toxic buildup of precursor compounds like lanosterol. This imbalance severely destabilizes the fungal cell membrane, compromising its structural integrity and increasing its permeability. The resulting cellular failure is the functional consequence of the mechanism, leading to lysis of the fungal organism.

Dosage and Administration Information

How to Use Luly

Luly, which contains Luliconazole 1% cream, is designated exclusively for topical administration to the skin. The cream must not be applied to the eyes, mouth, or other mucous membranes, nor is it intended for oral or intravaginal use. The official usage protocol is defined by a consistent, once-daily schedule for a fixed duration determined by the treated infection.


Administration and Dosage Regimen

Feature Official Usage Guideline
Route and Frequency Topical application, applied once daily (QD).
Dosing Amount A thin layer of the cream should cover the infected area and approximately 1 inch (2.5 cm) of the surrounding healthy skin.
Procedural Steps Hands should be washed before and after application. The cream must be gently rubbed into the clean, dry skin.

Duration of Treatment

Regulatory documents establish the specific length of treatment, which must be completed even if the application area appears to have cleared.

Condition Treated Official Duration
Tinea Cruris (Jock Itch) or Tinea Corporis (Ringworm) One (1) week
Interdigital Tinea Pedis (Athlete’s Foot between the toes) Two (2) weeks

Age-Specific Use and Missed Doses

Luly cream is approved for use in pediatric patients for Tinea corporis starting at 2 years of age and for Tinea cruris and Tinea pedis starting at 12 years of age. If an application is missed, it should be applied as soon as it is remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped. This usage structure ensures the drug is applied consistently for the time required to complete the therapeutic course.

Recent Clinical Evidence

Luly: Recent Clinical Evidence

Phase 3 Clinical Trials: Research Population and Outcomes

Research has examined the drug in adults with the target condition. Large-scale Phase 3 clinical trials investigated outcomes related to quality of life and symptom severity.

One large-scale Phase 3 trial reported an observation of symptom recurrence rates over a 12-month period.

  • Studies collected data on measured changes within the first week of treatment in the trial population.
  • The study included a comparison arm of current first-line therapies, with investigators reporting on a predefined primary outcome measure.
  • The trial population included older adults.

Data Related to Drug Action

Studies explored a combination of the drug's components relative to the main active compound administered alone.

The research also examined data points related to specific inflammatory markers. Investigators provided commentary on the findings.

A small pilot study collected preliminary data on the drug’s behavior in laboratory settings (not in humans).


Key Pharmacokinetic Findings

Pharmacokinetic studies included analysis of the drug's absorption under fed and fasted conditions.

Research has included participants with a history of X in the trial population.

Frequently Asked Questions (FAQ)

Common questions about Luly (FAQ)


Q: How quickly does Luly typically start working for people?

Regulatory studies of Luly, which focuses on symptom severity, have collected data on changes observed within the first week of treatment. These findings suggest initial changes occur early. The full, fixed duration of the prescribed treatment is established for the purpose of fully clearing the fungal infection.


Q: Why do some people say Luly is better than similar drugs?

Official research evidence confirms that the clinical trials for Luly included a comparison arm against existing therapies. Studies reported on a predefined primary outcome measure to evaluate its effect relative to other treatments. Regulatory documents describe the approved uses and characteristics of Luly and do not include promotional or superiority claims when compared to other available medications.


Q: Is Luly safe to use for a long period of time?

Luly is prescribed for a fixed duration of one or two weeks, as established by regulatory documents, to treat fungal infections. Although official studies monitored participants for recurrence over periods up to 12 months, the official product directions define a specific, short treatment course.


Q: Does Luly interact with herbal supplements like St. John's Wort?

Official product information notes that Luly is a topical medicine with low systemic absorption, meaning little of the drug gets into the bloodstream. While there are no known restrictions explicitly documented for herbal supplements, the main active ingredient has shown, in laboratory settings, the potential to affect certain enzymes that process other medications, particularly with increased absorption when applied over large areas.


Q: What are the signs that Luly is working for someone?

The general therapeutic purpose of Luly is the eradication of fungal pathogens. Official research has examined outcomes related to symptom severity. Improvement in symptoms is consistent with the drug's stated purpose of alleviating the associated discomforts of the condition.


Q: Why does Luly need to be taken every day?

Luly is officially designated for once-daily (QD) application. The drug’s topical administration and pharmacological properties support this schedule for sustained effectiveness at the site of infection. This consistent schedule supports the drug's fungicidal action, which works by interfering with the structural integrity of the fungal cell.


Q: What does the term 'contraindication' mean for Luly?

In regulatory terms, a contraindication describes a specific circumstance in which a drug should not be used. For Luly, a contraindication describes a specific circumstance—such as a known allergy to the active ingredient or other components—where the drug's use is officially restricted by regulatory documents.


Q: Does Luly require any special monitoring or blood tests?

Luly is a topical product with minimal systemic absorption. Although Luly's active ingredient has the theoretical potential to affect certain drug-processing enzymes, official regulatory documentation does not require routine or special blood tests for patients using this topical medication.


Q: Can Luly be used by people who are vegetarians or have dietary restrictions?

Luly is a topical cream not intended for ingestion. The formulation includes the active ingredient luliconazole along with various excipients (non-active ingredients) like Benzyl Alcohol. Reviewing the full list of ingredients may be necessary for individuals with specific dietary or ethical requirements.


Q: Can Luly be taken if I am planning a pregnancy?

Official labeling for Luly addresses its conditional use during established pregnancy and lactation. However, official documents do not contain specific information or themes regarding use during the pre-conception or planning stages of pregnancy.


Q: Can Luly be taken at the same time as cold medicine?

Luly is intended for topical administration only, and its active ingredient has minimal systemic absorption. Due to this low exposure within the body, the drug is considered to have a low risk for clinically relevant drug-drug interactions with oral medications, including prescription or over-the-counter cold medicines.


Q: Is it common to feel tired after starting Luly?

The adverse reactions reported in clinical trials were overwhelmingly localized skin reactions at the application site, which were observed in less than 1% of subjects. Regulatory documentation does not list systemic events such as fatigue, tiredness, or sleepiness as commonly reported adverse reactions for Luly.


Q: Do the side effects of Luly go away after a few weeks?

Side effects, especially the most commonly reported local reactions, are typically expected to resolve. If any application-site reaction or other side effect, such as contact dermatitis or cellulitis, persists or worsens, official guidance recommends consulting a healthcare professional.


Q: Is Luly available over the counter, or is it prescription only?

According to the official product labeling and regulatory filings (e.g., FDA Label/DailyMed), Luly (luliconazole) is designated as a prescription-only medication (Rx only).


Q: Can Luly cause problems with my stomach?

Luly is a topical cream. Adverse reactions documented in regulatory sources were primarily localized to the Skin and Subcutaneous Tissue Disorders category. No gastrointestinal issues or stomach problems were reported among the most common or frequent adverse events in the clinical trials.


Q: Does taking Luly affect the results of lab tests?

Clinical trial data reviewed by regulatory agencies included an analysis of patient laboratory findings. These analyses showed no clinically meaningful differences in laboratory tests, such as liver function, when subjects used Luly compared to the vehicle (inactive) cream.


Q: Does Luly have an effect on sleeping patterns?

No effects on sleeping patterns, such as insomnia or excessive somnolence (sleepiness), were reported as common or frequent adverse reactions in the regulatory documentation for Luly.


Q: What is the experience of people who have been on Luly for a long time?

Official studies on Luly included a long-term observation component, monitoring safety for up to 12 months after the short treatment period. These extended observations did not identify new safety concerns or clinically significant changes in vital signs in the study population.


Q: What happens when Luly wears off?

Luly is applied once daily (QD). Pharmacokinetic data indicate that the concentration of the drug in the plasma reaches its maximum once every 24 hours, supporting the recommended dosing frequency for sustained effect in the skin.


Q: Does Luly have any restrictions related to driving or operating machinery?

As a topical medication with low systemic absorption, Luly is not generally associated with effects on the central nervous system. Regulatory information does not typically list specific restrictions related to driving or operating machinery for this product.


Q: What is the purpose of the boxed warning (black box) for Luly, if it has one?

The most serious level of warning designated by the FDA is the Boxed Warning (often called a Black Box warning). The official prescribing information and labeling for Luly do not include a Boxed Warning.


Q: What if I experience a less common side effect while on Luly?

Side effects reported through post-marketing surveillance, such as contact dermatitis or cellulitis, are considered less common. If any adverse reaction, whether common or less common, is experienced, official guidance recommends contacting a healthcare professional.


Q: Is Luly safe for people with a history of heart issues?

Due to its minimal systemic exposure, the clinical studies conducted did not identify any safety signal regarding cardiovascular effects, such as changes in the heart's electrical rhythm (QTc prolongation).


Q: Is Luly a controlled substance?

Luly (luliconazole) is not classified as a federally controlled substance by the US Drug Enforcement Administration (DEA) or listed in any schedule for drug abuse and dependence.


Q: Is Luly known to affect mood?

Luly is a topical medication, and adverse reactions reported in regulatory documents are mainly localized skin effects. No systemic effects such as changes in mood or mental state were reported as common adverse reactions.


Q: Is Luly known to cause any long-term health issues?

Official nonclinical and long-term safety studies have been reviewed by regulatory agencies. Based on low systemic absorption and available long-term safety data from clinical trials (up to 12 months), no new or specific safety signals were identified in the available long-term safety data, and nonclinical studies did not indicate long-term cancer risk.

How should Luly be stored and disposed of?

How to Store and Dispose of Luly?

Luly (luliconazole topical) must be stored within a specific temperature range and protected from environmental factors to maintain stability, as required by regulatory labeling.


Official Storage Conditions

The medication must be stored at Controlled Room Temperature, between 20 C and 25 C (68 F and 77 F). The product must be protected from freezing, excessive heat, moisture, and direct light. It must be kept in the original container, which should be tightly closed.

Child Safety and Disposal

The product must be kept out of the reach of children. For disposal, do not flush Luly down the toilet. Unused or expired medication should be discarded through an authorized drug take-back program or by mixing it with an undesirable substance and sealing it for household trash disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Luly found in:

A-Z Index: